Bedrijfsoverzicht
Polyrizon Ltd. is a biotechnology entity focused on the development of medical device hydrogels formulated as nasal sprays within the Israeli market. The company operates specifically within the healthcare sector and the biotechnology industry, specializing in proprietary technologies designed to create barriers against allergen particulates and viruses through its Capture and Contain product line. With a market capitalization of $17.57M, an annual revenue figure marked as not available, and an employee count of 2, the organization presents a highly concentrated operational structure typical of early-stage research and development firms. The minimal valuation relative to its industry peers, combined with a workforce of only two employees, indicates that the company is in a pre-commercialization or early clinical stage where capital allocation is directed almost exclusively toward intellectual property development rather than scaled manufacturing or broad market distribution.
Financiële gezondheid
The financial performance of Polyrizon Ltd. over the trailing twelve months reflects a net income of $-3,335,000 and an EBITDA of $-5,907,000, while specific revenue data is not available for calculation. The substantial gap between the reported net income loss and the EBITDA loss highlights significant non-operating expenses or one-time costs that are not fully captured in the operating earnings metric, suggesting a cost structure heavily weighted toward research and development overheads. The company reports a free cash flow of $-2,566,625, which indicates a continued burn rate where cash outflows for operations and capital expenditures exceed cash inflows, limiting immediate financial flexibility without further external financing. Analyzing the three key margins reveals a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, which collectively indicate that the company is not yet profitable at the operational level and has not generated revenue sufficient to cover its cost of goods sold or operating expenses. In terms of balance sheet strength, Polyrizon holds $12.27M in cash against $0 in debt, resulting in a debt-to-equity ratio marked as not available due to the lack of debt obligations, which points to a highly conservative leverage position rather than a leveraged one. The current ratio stands at 29.03, a figure that suggests an exceptionally strong short-term liquidity position where current assets vastly exceed current liabilities, providing ample buffer for operational continuity despite the cash burn. Furthermore, the return on equity is -25.4% and the return on assets is -28.9%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested, a common characteristic for biotechnology firms in the development phase.
Waarderingsbeoordeling
Valuation multiples for Polyrizon Ltd. include a trailing P/E ratio and a forward P/E ratio, both of which are not available due to the absence of earnings per share data. The lack of a trailing or forward P/E ratio implies that traditional earnings-based valuation models cannot be applied, as the company has not yet achieved profitability or a stable earnings trajectory that would allow for meaningful comparison with profitable peers. The price-to-book ratio is recorded at 0.83, indicating that the market values the company at a discount to its book value, which may reflect the high risk associated with the biotechnology sector or the difficulty in valuing intangible assets like proprietary technology at book value multiples. Alternative valuation metrics such as the price-to-sales ratio and the EV/EBITDA ratio are also not available or negative at -0.90 respectively, suggesting that sales-based valuation is similarly constrained by the lack of revenue history and that the EV/EBITDA multiple is distorted by the negative earnings profile. The 52-week high for the stock is $2235.00 and the 52-week low is $2.88, highlighting an extreme volatility range where the current price dynamics are significantly influenced by speculative trading rather than fundamental value discovery. Although the beta value is not available, the price range suggests that the stock experiences substantial price swings relative to its historical trading bands, a characteristic often seen in small-cap biotechnology stocks with limited analyst coverage.
Growth & Income
The revenue growth and earnings growth rates for Polyrizon Ltd. are not available, which precludes a direct comparison of earnings expansion relative to revenue growth and prevents any assessment of the company's historical growth trajectory. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the organization retains all available cash flow to reinvest into its research and development activities rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company follows a strategy of capitalizing on growth opportunities through internal funding and cash reserves rather than providing an income stream to investors. Consequently, the overall growth and income profile is characterized by a lack of current income generation and an undefined historical growth rate, with the company relying entirely on its $12.27M cash reserve and the potential future success of its medical device hydrogel technologies to drive future expansion.